FIELD: medicine.
SUBSTANCE: invention relates to immunology. Antibodies to an insulin-like growth factor receptor 1 (IGF-1R) and their antigen-binding fragments are offered. Also disclosed is a method of detecting the presence and/or localization of tumour cells, a method of determining the percentage of tumour cells, a method for determining the level of expression of IGF-1R in tumour cells, a method for determining quantitative evaluation of IGF-1R tumour cells or tumour. Also disclosed is a method for determining whether an oncogenic disease is susceptible to treatment, a method for determining the effectiveness of the therapeutic regimen, method of selecting a patient, as well as a set for detecting tumour cells and a kit for determining whether a drug treatment for the patient with oncogenic disorder is beneficial.
EFFECT: present invention can find further application in therapy of oncogenic diseases, particularly cancer.
15 cl, 9 dwg, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706967C2 |
| I-3859 ANTIBODY APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636032C2 |
| NEW ANTIBODY TO CXCR4 AND ITS APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636345C2 |
| ANTI-cMet ANTIBODY AND USE THEREOF FOR DETECTION AND DIAGNOSIS OF CANCER | 2010 |
|
RU2582265C2 |
| NEW MODULATORS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2627176C2 |
| NOVEL ANTIBODY FOR DIAGNOSIS AND/OR PROGNOSIS OF CANCER | 2011 |
|
RU2651513C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
| NOVEL MODULATORS AND METHODS FOR USE THEREOF | 2011 |
|
RU2592672C9 |
